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Abstract
Introduction: Hypoxia-inducible factor-1 (HIF1) controls the expression of genes involved in the cellular response
to hypoxia. No information is available on its expression in critically ill patients. Thus, we designed the first clinical
study in order to evaluate the role of HIF1a as a prognosis marker in patients suffering from shock.
Methods: Fifty consecutive adult patients with shock and 11 healthy volunteers were prospectively enrolled in the
study. RNA was extracted from whole blood samples and expression of HIF1a was assessed over the first four
hours of shock. The primary objective was to assess HIF1a as a prognostic marker in shock. Secondary objectives
were to evaluate the role of HIF1a as a diagnostic and follow-up marker. Patient survival was evaluated at day 28.
Results: The causes of shock were sepsis (78%), hemorrhage (18%), and cardiac dysfunction (4%). HIF1a expression
was significantly higher in the shock patients than in the healthy volunteers (121 (range: 72-168) versus 48 (range:
38-54) normalized copies, P <0.01), whatever the measured isoforms. It was similar in non-survivors and survivors
(108 (range 84-183) versus 121(range 72-185) normalized copies, P = 0.92), and did not significantly change within
the study period.
Conclusions: The present study is the first to demonstrate an increased expression of HIF1a in patients with shock.
Further studies are needed to clarify the potential association with outcome. Our findings reinforce the value of
monitoring plasma lactate levels to guide the treatment of shock.
Introduction
Shock states are defined by an acute circulatory failure
leading to prolonged and intense tissue hypoxia that
may lead to death. Tissue hypoxia is accompanied by a
decreased production of ATP in the mitochondria.
Hypoxia-inducible factor-1 (HIF1) is a heterodimer
made of two sub-units (a and b) [1,2]. The gene coding
for HIF1a is on chromosome 14 (14q21-q24) [3]. HIF1a
protein concentration is correlated to cellular oxygen
concentration [4]. In hypoxemic conditions, HIF1a is
not degraded and accumulates in the cellular nucleus
[5]. The effects of HIF1a are stimulation of erythropoi-
esis, glycolysis, angiogenesis, and vasodilation [1]. In
normoxic conditions, HIF1a and its messenger RNA
(mRNA) have a very short half-life of five minutes [6,7].
This suggests that HIF1a is an immediate surrogate
marker of cellular oxygenation.
In human shock states, plasma lactate is routinely used
as a marker of tissue hypoxia. This marker has been vali-
dated for the detection of shock states as well as the pre-
diction of patient outcomes [8,9]. However, plasma
lactate concentrations are influenced by both the produc-
tion and clearance of lactate. This can be a limitation for
the interpretation of plasma lactate concentrations at the
bedside. The main objective of the present study was to
evaluate the potential prognostic role of HIF1a in ICU
patients with shock states. Secondary objectives were to
evaluate the role of HIF1a as a detection marker and its
correlation with plasma lactate concentrations.
Materials and methods
Patients
The study received approval of the Ethics Committee (n°
2009-A00105-52) and was conducted in a 15-bed ICU of
a teaching hospital (928 beds). Inclusion criteria were
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≥18 years of age and ≤80 years of age, and shock. Shock
was defined as follows: hypotension requiring fluid infu-
sion and use of vasopressors, and plasma lactate concen-
trations >2 mmol/L. The shock should be related to
sepsis, bleeding, or cardiac dysfunction. The exclusion
criteria were pregnancy and patients without a social
security number or deprived of freedom. After a next of
kin gave informed consent, the patients with shock were
prospectively included.
The patients had to be enrolled within six hours after
admission to the ICU. All enrolled patients were
equipped with a central line and an arterial catheter.
Blood samples for HIF1a (italic refers to mRNA
throughout the manuscript) measurements were col-
lected on PaxgeneTM tubes (BD, Franklin Lakes, NJ,
USA) and stored at -80°C until RNA extraction. Sam-
pling was performed at the time of shock detection
(H0), and after 1 hour (H1), 3 hours (H3), and 4 hours
(H4). These time points were selected to follow the
early steps of the interventions in patients with shock.
The following variables were collected: age, sex, body
mass index, and admission simplified acute physiology
score (SAPS) II [10], sequential organ failure assessment
(SOFA) score [11], vital signs, type of shock, type of
ventilation, drugs needed for the treatment of shock
states, biochemical variables, blood cell count and coa-
gulation variables. In addition, arterial blood gas and
plasma lactate concentrations were measured at each
time point. Mortality was evaluated at day 28. Data on
the duration of mechanical ventilation, vasopressor infu-
sion, and ICU stay were also obtained. Treatment goals
were based on most available guidelines [8]. Briefly,
mean arterial pressure (MAP) was targeted at ≥65
mmHg, urine flow ≥0.5 ml/kg/hour, and central venous
oxygen saturation (ScvO2) ≥70%, as described elsewhere
[12].
RNA extraction and quantification of HIF1a variants
Total RNA was isolated using the PAXgene™ Blood
RNA Kit (Qiagen, Courtaboeuf, France) according to the
manufacturer’s instructions. A total of 1µg of RNA was
reverse transcribed with 200 UI MMLV Reverse Tran-
scriptase following the EAC (Europe Against Cancer)
protocol [13]. The cDNA was diluted in a final volume of
50 µl. Amplification and quantification of HIF1a variants
were performed as previously described with some modi-
fications of primers and probe sequences (Additional file
1, Figure S1) [14]. Transcripts of the gene coding for TBP
(TATA box-binding protein) were also quantified as the
endogenous RNA control. Final HIF1a mRNA concen-
trations were expressed in normalized copy numbers as
previously described [14].
The gene HIF1a is composed of 15 exons, resulting in
a principal transcript (HIF1aWT) [3,15] and seven
alternative splice variants which have been reported in
human cell lines [16-20]. Amplification of HIF1aWT
showed that it was expressed by circulating blood cells,
as well as the splicing variants HIF1aTAG and HIF1a736
(Figure 1). HIF1a516 and HIF1a557 splice variants tested
two isoforms coding for negative dominants. These two
isoforms were not or were poorly expressed by circulat-
ing blood cells. Relative expression of different isoforms
was similar between patients and volunteers (Figure 1).
In a subgroup of six patients, at H0, blood was col-
lected from both arterial and venous lines. With regard
to the expression of HIF1a, no difference was found
between the venous and arterial blood samples (data not
shown). Then, a group of 11 healthy volunteers, non-
smokers, was evaluated for HIF1a expression and used
as controls.
Statistical analysis
From previous studies [14,21], 44 patients with shock
were required to achieve a predictive value of 90% with
a bias <5% and a 5% risk a. Data were analyzed using
the software SPSS and R. Quantitative variables are
expressed as median and interquartile range. Qualitative
variables are expressed as absolute counts and percen-
tages. Differences between groups were tested using
non-parametric tests (Mann-Whitney and Kruskall-
Wallis tests). A P level of 0.05 or less was considered
significant.
Results
Patient characteristics
Fifty patients with shock (average age 57 (range: 18 to 80
years) and 11 healthy volunteers (average age 50 (range:
29 to 70 years) were prospectively included. Women
Figure 1 Expression of different HIF1a variants in shock
patients (black bars) and controls (grey bars).
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represented 25% of the cohort of patients and 27% of the
cohort of healthy volunteers. The HIF1a expression was
unaffected by sex (P = 0.7) or age (P = 0.8). The causes of
shock were sepsis, bleeding, and cardiac dysfunction in 39
(78%), 9 (18%), and 2 (4%) cases, respectively (Table 1).
Plasma bilirubin concentration and SOFA score differed
significantly in survivors and non-survivors (Table 1).
HIF1a expression
At any time points of the study period, the expression
of HIF1a was significantly increased in the patients
with shock (Figure 2). At H0, 121 (range: 72 to 168)
normalized copies were found in patients with shock,
as compared with 46 (range: 38 to 54) normalized
copies in healthy volunteers (P <0.01). The detailed
values for each time point are presented in Table 2. Of
note, the expression of HIF1a did not differ according
to the type of shock (data not shown). We did not find
a relation between the expression of HIF1a and the
absolute number of white blood cells (data not shown).
HIF1a expression, plasma lactate levels, and outcome
Independently of time points, the HIF1a expression did
not differ in the survivors and non-survivors (Table 2).
In contrast, with the exception of H0, plasma lactate
levels were higher in the non-survivors than in the sur-
vivors (Table 3). A weak positive correlation was found
between HIF1a expression and plasma lactate concen-
trations (r2 = 0.1; P = 2.10-5).
No correlation was found between the HIF1a expres-
sion and admission SAPS 2, shock duration, use of
mechanical ventilation, SOFA score, and length of ICU
stay. The changes in HIF1a expression between H0 and
H4 were not predictive of outcome (Figure 2). The
HIF1a expression was not correlated with hemoglobin,
PaO2, and PaO2/FiO2 ratio.
Expression of HIF1a and response to shock treatment
The expression of HIF1a was significantly higher in 24
patients who received more than two liters of fluid
expansion: 124 (range: 100 to 168) normalized copies
versus 87 (range: 44 to 141) normalized copies (P =
0.02). No difference was found according to the type of
administered fluid (crystalloid versus colloids). The
HIF1a expression was not correlated with the dose of
vasopressors.
Discussion
The present study is the first to show an increased
expression of HIF1a in patients with shock, as com-
pared with healthy volunteers. The changes in HIF1a
expression over time were not correlated with the
patient outcome or their treatment responses. Especially,
according to our findings, HIF1a expression cannot
serve to determine the true level of tissue oxygenation.
A significant increase in HIF1a expression was
observed in the patients who received more than two
liters of fluid expansion. Nevertheless, no correlation was
found with markers of severity, such as MAP, SAPS2 and
SOFA score. This finding invites us to hypothesize that
this increase was related to a specific effect of fluid infu-
sion. Among several hypotheses, one may consider that
large fluid resuscitation can impair tissue oxygenation
[22]. Another explanation would be that fluid administra-
tion was related to the severity of vasodilation, which in
turn may be related to tissue-hypoxia. Further investiga-
tions are needed to clarify this issue. Larger groups of
patients should be evaluated in order to elucidate such a
specific effect.
HIF1a has an ultra-short half-life [23,24]. One interest-
ing point of the present study is that during the four hours
of the study period, the expression of HIF1a was stable.
Our initial hypothesis was that due to its ultra-short
Table 1 Characteristics of the patients according to their survival (day 28).
Variables All patients
number = 50
Non-survivors
number = 16
Survivors
number = 34
P
Mechanical ventilation (%) 32 (64) 12 (75) 20 (59) 0.35
Plasma lactate concentrations (mmol/L) 3.1 (1.9-4.8) 3.8 (2.4-7.2) 3 (1.9-4.3) 0.16
MAP (mmHg) 67 (60-72) 70 (52-72( 65 (61-71) 0.89
Plasma creatinine (µmol/L) 112 (85-170) 129 (96-184) 99 (80-155) 0.10
Plasma bilirubin (mmol/L) 11 (6-21) 18 (12-32) 9 (6-18) 0.03
PaO2/FiO2 ratio 186 (112-374) 169 (97-322) 194 (133-376) 0.44
PaO2/FiO2 <150 24 (48) 8 (50) 16 (47) 0.96
SAPS 2 46 (32-61) 55 (36-72) 45 (27-55) 0.06
SOFA score 9 (7-11) 10 (9-12) 8 (6-9) 0.003
Hemoglobin level H0 (g/dL) 10.0 (8.7-11.4) 10.6 (9.0-11.3) 10 ([8.5-11.5) 0.48
MAP, mean arterial pressure; PaO2/FiO2, partial pressure in oxygen related to the inspired fraction of oxygen; SAPS 2, Simplified Acute Physiology Score; SOFA ,
sequential organ failure assessment.
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half-life, HIF1a could provide an immediate reflection of
tissue oxygenation. We failed to demonstrate this effect or
tissue oxygenation remained unaffected by time and treat-
ment steps. A persistent HIF1a expression has already
been demonstrated in cases of lipopolysaccharide stimula-
tion and during a sustained inflammatory response
[25-28]. Such situations are obviously present in the study
patients. A major inflammatory response is present in
patients with shock due to the ischemia-reperfusion
induced by the treatment of shock [23,29-33]. Because
plasma lactate concentrations are not only dependent on
production but also on its metabolism, we hypothesized
that HIF1a would be a better marker. Our study clearly
shows that, at the bedside, lactate remains a better marker
of shock than HIF1a. The quantity of protein may be a
more accurate marker than the gene expression. Future
studies need to clarify this point.
HIF1a is a biomarker of states of cellular hypoxia. Its
interest as a marker of outcomes in patients with shock
has never been evaluated before. Nevertheless, our
results show that, despite attractive speculations about
biomarkers, clinical trials are crucial to evaluate their
actual role [4,5]. In the present study, the expression of
HIF1a is markedly increased during shock states. The
observed increase could be related to the tissue ischemia
of shock states or to the inflammatory response. No
relation was found between HIF1a expression and oxy-
genation variables. However, our results show a trend
toward an increased expression in patients with low
levels of hemoglobin (Hb >8 g/dL: 109 (range: 84 to
174) HIF1a copies versus Hb <8 g/dL: 161 (range: 74 to
270) HIF1a copies; P = 0.4). Larger samples of patients
would be required in order to validate this trend. The
expression of HIF1a was wider than expected in our
rationale. The wide dispersion of the values may be
explained by the ultra-short half-life of HIF1a. This may
have affected the power of the study.
In our study, HIF1a mRNA expression seems to fail
to reflect hypoxia. Several hypotheses may explain this
result. First, we measured the expression of HIF1a
mRNA in plasma. Actually, in the case of hypoxia, its
Figure 2 Expression of HIF1a over time in survivors (white circles) and non survivors (black circles). The horizontal bar indicates the
median for each group.
Table 2 Normalized copies of HIF1a in patients with
shock according to their survival (day 28) and controls.
Time Patients
number = 50
Non-survivors
number = 16
Survivors
number = 34
P
H0 109 (78-185) 108 (84-183) 121 (72-185) 0.92
H1 132 (69-169) 123 (99-189) 142 (68-167) 0.88
H3 123 (72-177) 120 (81-180) 123 (68-157) 0.57
H4 109 (73-150) 114 (75-140) 106 (68-150) 0.97
Controls
number = 10
baseline 46 (38-54)*
*P < 0.01 as compared with patients at H0.
Table 3 Plasma lactate (mmol/L) according to the survival
of patients at day 28.
Time All patients
number = 50
Non-survivors
number = 16
Survivors
number = 34
P
H0 3.1 (1.9-4.8) 3.6 (2.4-7.2) 3.0 (1.9-4.3) 0.16
H1 2.8 (1.8-3.6) 3.4 (2.4-7.3) 2.4 (1.8-3.2) 0.04
H3 2.5 (1.7-3.2) 3.4 (2.3-6.3) 2.3 (1.7-2.7) 0.03
H4 2.5 (1.9-3.4) 3.7 (2.5-5.3) 2.4 (1.6-3.0) 0.01
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expression may be more accurate in tissue than in
blood. However, regarding our study goals, the collec-
tion of tissue biopsy was irrelevant. Second, we may
hypothesize that the protein of HIF1a may better reflect
tissue hypoxia than its mRNA expression. However, the
determination of the protein levels is time consuming,
whereas that of RNA levels can be performed in a short
time. Our study was aimed at providing an early marker
in real-life clinical practice. Finally, divergently from
HIF1a, plasma lactate levels may reflect pyruvate accu-
mulation rather than cell hypoxia in sepsis and injury
[9]. The evaluation of HIF1a values beyond four hours
may also bring new evidence of its role in patients with
shock. Future studies are needed to determine whether
its expression during late phases of shock may be
related to early interventions. Finally, it is important to
consider that the present study focused on blood deter-
minations. This could not reflect with enough accuracy
the state of ischemia at the tissue level [21].
Conclusions
The present study is the first to show the increased
expression of HIF1a, a transcription factor that controls
genes implied in the response to cellular ischemia, in
patients with shock. Within the limitations of the study,
HIF1a expression was not correlated with the outcome
of patients. Further studies including larger groups of
patients are warranted to clarify this issue.
Key messages
• Hypoxia-inducible factor 1 alpha (HIF1a) is a tran-
scription factor that controls the expression of genes
in response to cellular hypoxia
• HIF1a mRNA is elevated in patients with shock, as
compared to healthy volunteers
• HIF1a expression was not correlated to patient
outcome
• HIF1a expression over the first hours of shock
management was independent of clinical evolution
and outcome
• To assess patients with shock, plasma lactate levels
seem better than HIF1a expression
Additional material
Additional file 1: Figure S1. RT-PCR primers pairs location. Schematic
representation of the location of the various pairs of primers used to
amplify several splicing variant of HIF1a.
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